P324: Management of risk in a country in crisis: hepatonephritis cases related to artemisinin- based combinations therapy
© Daubrey Potey et al; licensee BioMed Central Ltd. 2013
Published: 20 June 2013
To analyze risk management when occurred hepatonephritis cases related to Artemisinin-based Combinations Therapy.
A technical committee of management of hepatonephritis cases has been set up by the health ministry. The terms of references were: 1) state of knowledges on the subject from the pharmacovigilance database of Côte-d’Ivoire; 2) Carrying out of an investigation in public and private hospitals; 3) start -up a plan of communication for the health professionals and population.
Results: States of knowledges: for 10 years, serious Adverse Drug reactions have been notified (57%), like black fever, hepatonephritis and serious hepatitis cases related to any antimalarial monotherapies : amodiaquin, artemisinin derivatives and quinine. Retrospective study: we collected 100 files. The principal damage was hepatic (63%), hepatorenal (26 %) and hematologic (19%). Antimalarial drugs implicated were: quinine (30,4%), artemether-lumefantine (21,4%) and artesunate-sulfamethopyrazine (13,6%)..Prospective study: We have analyzed 25 cases over 3 months of investigation.
Conclusion: Start-up of a plan of communication: we drafted and sent an alarm note and recommendations of good use of antimarial combinotherapies to prescribers and dispensers.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.